^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

HMN-176

i
Other names: HMN-176
Associations
Trials
Company:
Nippon Shinyaku
Drug class:
PLK1 inhibitor
Associations
Trials
almost2years
Inhibition of Polo-like Kinase 1 by HMN-214 Blocks Cell Cycle Progression and Inhibits Neuroblastoma Growth. (PubMed, Pharmaceuticals (Basel))
HMN-214 is a prodrug of HMN-176 and is known to selectively interfere with PLK1 function. In the NB 3D spheroid tumor model, HMN-214 significantly and in a dose-dependent manner inhibits spheroid tumor mass and growth. Overall, our study highlights that targeting PLK1 using HMN-214 is a novel therapeutic approach for NB.
Journal
|
MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • CHEK2 (Checkpoint kinase 2) • PLK1 (Polo Like Kinase 1) • CHEK1 (Checkpoint kinase 1) • CDK2 (Cyclin-dependent kinase 2) • CDK1 (Cyclin-dependent kinase 1) • CCNB1 (Cyclin B1)
|
MYCN amplification
|
HMN-176 • HMN-214